Business
Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
OLDSMAR, Fla., May 08, 2026--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the "NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards.
About this update from Cryo-cell International, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/447e8c8826bd759a743045aa6814a2a2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d8bsSsqy3ratf793WoVDWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/447e8c8826bd759a743045aa6814a2a2","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/pJo1SN86A_8RkDcJ2bk52A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/447e8c8826bd759a743045aa6814a2a2","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/3oUsMV9BP6IpCUMRhv5OpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/447e8c8826bd759a743045aa6814a2a2","width":1024,"height":512}},"lazy":false},{"type":"text","content":"OLDSMAR, Fla., May 08, 2026--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the "NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards.","length":389,"tagName":"p"},{"type":"text","content":"As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders’ deficit as of November 30, 2025, and (ii) net losses in two of its three most recent fiscal years ended November 30, 2023, November 30, 2024 and November 30, 2025.","length":367,"tagName":"p"},{"type":"text","content":"On April 8, 2026, the Company submitted a plan to address these deficiencies. NYSE Regulation has reviewed and accepted the plan, granting Cryo-Cell a compliance period through September 9, 2027 (the "Plan Period"). During this time, the Company’s common stock will continue to be listed and traded on NYSE American, subject to ongoing review and adherence to the plan’s initiatives.","length":393,"tagName":"p"},{"type":"text","content":"There can be no assurance that the Company will be able to regain compliance with the NYSE American cont...